The world treatment-resistant depression therapies market is expanding quickly due to the ageing population and the rise in anxiety and depression among adults. Its total value is anticipated to reach US$ 4.0 billion by 2033 due to the development of entirely new medications employing state-of-the-art methods such as nasal inhalants or direct intravenous injection, which offer relief in circumstances where traditional therapies have previously proved ineffective.
Despite the common use of traditional antidepressants to treat depression, they often require up to six weeks in order for patients to see an effect. However, new research has found that administering antidepressant medication through intranasal means can produce better results more quickly – within a mere 24 hours! This was showcased by Novartis Pharmaceuticals’ upcoming pipeline antidepressant MIJ821 and published in January 2022’s edition of Pharmacopsychiatry magazine; where clinical trials saw participants demonstrate significant reductions in depressive episodes after only one day..
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-15965
In addition, the overall findings displayed that treatment with intranasal esketamine in amalgamation with a novel oral antidepressant was more efficient than a placebo plus an oral administration. The intranasal esketamine showcased a prompt drop of depressive symptoms and postponed its relapse time. Furthermore, such increasing research & development for advanced drugs through other routes of administration is projected to surge the demand for drugs, thereby augmenting the overall market growth.
As per the World Health Organization (WHO), prevalence of mental health disorders as well as conditions is increasing across the globe. There has been a 13% increase in mental health conditions and other depressive disorders in the last decade. According to the U.S. Department of Health and Human Services (HHS), in 2020, among adolescents between ages 12 and 17, 17.0% (about 4.1 million population) had major depressive episode (MDE), and 12% (about 2.9 million people) had MDE with severe impairment.
Key Takeaways:
- Global Treatment-Resistant Depression Therapeutics market was valued at US$ 1.55 Billion by 2022-end
- From 2018 to 2022, the market demand expanded at a CAGR of 3.3%
- By drug type, the NMDA segment of the market constitutes the bulk of the market with a market share of 49%
- By Distribution Channel, the Hospital Pharmacies segment dominates the market with a share of 47%
- From 2023 to 2033, Treatment-Resistant Depression Therapeutics sales are expected to flourish at a CAGR of 9.0%.
- By 2033, the market value of Treatment-Resistant Depression Therapeutics is expected to reach US$ 4.0 Billion
“The rising geriatric population is one of the factors that is anticipated to boost the growth of treatment-resistance depression treatment market, as the treatment-resistance depression treatment is high in this age group population,” remarks an FMI analyst.
Competitive Landscape
Prominent players in the Treatment-Resistant Depression Therapeutics market are Janssen Global Services, LLC, AbbVie Inc., Sandoz International GmbH (Novartis AG), H. Lundbeck A/S, Par Pharmaceutical (Endo International plc), Otsuka Pharmaceutical Co., Ltd., and AstraZeneca, among others.
Recent Developments:
- In August 2022, Merck Sharp & Dohme LLC initiated Phase IIa clinical trial to evaluate the safety and efficacy of MK-1942 among treatment-resistant depression patients.
- In July 2022, Novartis Pharmaceuticals announced that it would initiate a Phase 2 clinical trial of MIJ821 (ketamine) for treatment-resistant depressive disorders in September 2022.
- In May 2022, COMPASS Pathways presented positive data for Phase IIb study of COMP360 psilocybin therapy for Treatment-Resistant Depression Therapeutics at the American Psychiatric Association annual meeting in New Orleans.
- In February 2022, Denova Biopharma secured U.S. FDA approval to initiate a Phase 2b clinical trial to analyze the efficacy and safety of DB104 (liafensine) in patients with treatment-resistant mood disorder.
Know More About What the Treatment-Resistant Depression Therapeutics Market Repost Covers
Future Market Insights offers an unbiased analysis of the global Treatment-Resistant Depression Therapeutics market, providing historical data for 2018-2022 and forecast statistics from 2023 to 2033.
To understand opportunities in the Treatment-Resistant Depression Therapeutics market, the market is segmented on the basis of drug type, and distribution channel across five major regions.
Have a Look at Related Reports of Healthcare domain:
Endoscopic Closure Systems Market Share: Global endoscopic closure systems market demand is anticipated to be valued at US$ 294.4 Million in 2022, forecast a CAGR of 6.3% to be valued at US$ 579.4 Million from 2022 to 2032.
Companion Diagnostics Market Size: The global companion diagnostics market is predicted to garner a revenue of about US$ 5152.064939 million by 2032, up from US$ 2452.653722 million in 2022 with a CAGR of 7.1% during the forecast period.
Cell-Free Fetal DNA Testing Market Sales: The cell-free fetal DNA testing marketis to capture a CAGR of 10.9% during the forecast period. The market is projected to be valued at US$ 1,349.54 million in 2022, and is likely to be valued at US$ 3,797.53 million by 2032.
Gastrointestinal Rare Diseases Treatment Market Outlook: The global gastrointestinal rare diseases treatment market is expected to accumulate a value of US$ 1,965 Million by registering a CAGR of 3.7% in the forecast period 2022 to 2032.
Key Segments:
Treatment-Resistant Depression Therapeutics Market by Drug Type:
- NMDA
- Antidepressants
- Antipsychotics
- Others
Treatment-Resistant Depression Therapeutics Market by Distribution Channel:
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
Treatment-Resistant Depression Therapeutics Market by Region:
- North America
- Latin America
- Europe
- South Asia & Pacific
- East Asia
- Middle East & Africa
Elevate Strategy: Tap into Analyst Expertise Now:
https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-15965
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
